Login

Company Executives

Officer Age In this role Joined 2025 pay Source
Adam S. Grossman Also a director
Founder, President, Chief Executive Officer and Director
49 Not stated Not stated $10,237,326
Paul Terence Kohler, Jr.
Chief Financial Officer and Treasurer
48 Since 2026
this year
2025 $2,296,949
Terry Kohler
CFO and Treasurer
Title from the Form 4 dated Jul 16, 2026
Not stated Not stated Not stated Not reported
Kaitlin Kestenberg
Chief Operating Officer and SVP, Compliance
39 Since 2024
2 years
2012 $3,488,647

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
5 of 5
stated in the proxy; 2 not stated
Average tenure
11.6 years
from year joined
CEO also chairs the board
No
Steven A. Elms
Director Age On board Independent Committees Other public boards 2025 pay Source
Steven A. Elms
62 2007
19 years
Independent
Governance and Nominations Committee
Elevation Oncology, Marker Therapeutics $446,235
Adam S. Grossman
49 2007
19 years
Not stated None stated None stated Paid as CEO
Alison C. Finger
62 2023
3 years
Independent
Governance and Nominations Committee
None stated $416,235
Eduardo Rene Salas
64 2024
2 years
Independent
Audit Committee
None stated $412,485
Young T. Kwon, PhD
54 2021
5 years
Independent
Compensation Committee · Chair Audit Committee · Chair
None stated $444,985
Jerrold B. Grossman
78 2007
19 years
Not stated None stated None stated Not stated
Lawrence P. Guiheen
75 2012
14 years
Independent
Governance and Nominations Committee · Chair
None stated $434,985

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 15, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support